Please assess the completion status of the following clinical trial:

Trial Title: Pemetrexed in Patients With Chemosensitive and Chemoresistant Relapsed Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histological or cytological proof of neuroendocrine cancers (including small cell cancers of any site \[including lung\] or poorly differentiated neuroendocrine cancers of the lung with (unidimensionally) measurable disease as per the RECIST criteria~* Chemoresistant or chemosensitive disease~* Patients must have received treatment with at least one but not more than 2 prior chemotherapy regimens, including one regimen containing a platinum agent~* Radiation therapy must have completed their radiation at least 14 days prior to being registered for protocol therapy, and toxicities due to radiation must have recovered to \< grade 1 or baseline prior to registration~* Negative pregnancy test~Exclusion Criteria:~* No clinically significant infections as judged by the treating investigator~* No symptomatic CNS metastasis~* No radiation to \> 25% of the marrow containing spaces~* No previous treatment with pemetrexed~* No uncontrolled pleural effusions~* No current breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Pemetrexed for patients with chemosensitive and chemoresistant relapsed small cell lung cancer.

Based on this trial design, predict the completion outcome and termination type (if applicable).